A Long-Term, Open-Label, Study on Schizophrenia

The study includes 2 treatment periods. Study Period I will begin at participant randomization (enrollment into Study HBBO) and continue through the first 2 years of treatment. Study Period II will be only for participants randomized to treatment with LY2140023, and will begin after the participant has completed the second year of treatment. Participants who qualify for enrollment will be randomized in a 3:1 ratio (LY2140023 versus standard of care, respectively) into 2 treatment groups: flexible, twice-daily dose of LY2140023 or standard-of-care (olanzapine, risperidone, aripiprazole, or quetiapine). Those assigned to LY2140023 will have the option to continue on LY2140023 after 2 years if deemed appropriate by the investigator.